100% tissue coverage and fill in 30 days* with no infections1
In the largest real-world study of lower extremity reconstructions, Myriad delivered exceptional value @ $253.90 (USD)** per defect.
- 130 lower extremity defects in 120 patients
- Minimal exclusion criteria
- Patients at a high risk of amputation
*Median 30.0 days (IQR: 26.9, 33.1) **Median product cost
Key Study Takeaways
Complete coverage and volumetric fill in 30 days.
- Exposed bone and tendon
- Presence of osteomyelitis
- Patients with diabetes and/or vascular disease
- Poor medical status (ASA 3 or 4)
ASA, American Society of Anesthesiologists
Dr. John C. Lawlor, DPM, discusses how he achieved coverage and fill in a case with an exposed calcaneus.
Dr. John C. Lawlor, DPM, discusses management of a complex patient from this study.
Zero infections. No complications or graft loss.
The majority of defects were CDC grade III (contaminated), with 47.7% having confirmed osteomyelitis.
Despite these complexities, zero infections, complications or graft loss were reported.
Patients were at high risk of amputation
Myriad demonstrates substantial value
In a cost comparison analysis, the Myriad median cost per defect was $253.90 (USD), a cost difference of up to 195% compared with other dermal matrices.
In a comparison of the cost to treat an equivalent cohort of patients with other dermal matrices which also included product re-application rates, Myriad was shown to provide substantial cost difference.
Product applications, median (IQR)
Case studies presented by lead author Dr. Lawlor
Related case studies
Wide Excision
3 Months post STSG
Abigail E. Chaffin, MD, FACS, CWSP, MAPWCA
Week 0
Week 11
Anthony J. LaLama, DPM
Initial Defect
Week 8
James Geiger, Jr. DPM, CWSP
Downloadable Resources
Find out more about Myriad use in lower extremity defects.
